Abstracts

ABSTRACT MANAGEMENT SYSTEM

Please read the following guidelines carefully in order to successfully use the system.

Step 1: Create an account for CUOS 2019 

Go to: https://cuos.ca 

Click on: “Click here to create a new account” and complete your profile

Step 2: Submit your abstract

On your Dashboard click on “My Abstracts” to submit your abstract. If you have any questions about the abstract submission process, please email leona@iseventsolutions.com

Important Dates

Accepted / rejected abstracts notifications will be sent out the week of November 12, 2018 

Deadline to accept invitation to present & complete profile: December 3, 2018

* Registration fee for presenters is waved.

 

A. Submission Terms

  1. Rule of two. This means that each presenter can only present two abstracts at the meeting (2 podium or 2 posters or 1 podium and 1 poster). Submitters can submit as many abstracts as they wish. If more than 2 abstracts get accepted, the submitter must appoint a co-author to present.
  2. Abstracts must be written and presented in English.
  3. Submitted abstracts undergo a blind review by peer-reviewers. Acceptance is based on scientific merit and originality.
  4. While abstracts may be submitted as podium or unmoderated poster presentation types, the Scientific Committee reserves the right to assign final presentation type in the best interest of the program.
  5. Multiple abstracts by the same authors based on the same study population or data may be disqualified without further consideration.
  6. The work covered by the abstract must not have been published as a manuscript before September 7, 2018.
  7. Abstracts that have been accepted for presentation at another major urological meeting must be disclosed. This can be emailed directly to the Program Manager (leona@iseventsolutions.com).
  8. Trials in progress can be submitted, but please note the committee will review and take into account whether or not the information is presentable or not with the data accumulated.
  9. In regards to production deadlines, as of November 1, 2018, all presenting authors must be registered and must have paid their registration fees to keep their abstract in the program. Any changes to the presenting author will not be reflected in the CUAJ after this date. 
  10. Authors are responsible for proofreading their abstract before submitting, particularly with regard to general orthography, as well as author names/order and affiliations. CUAJ will edit all submissions for consistency and formatting.

B. Abstract Format

  • Title:
    • The title should clearly define the topic and contain no abbreviations.
    • There is a character limit of 200 characters including spaces.
    • Enter the title as you were writing a sentence, Only CAPITALIZE the first letter of the sentence and proper nouns, nothing else.
    • Do not use punctuation at the end of the sentence UNLESS it is a question mark (?) or exclamation point (!)
    • No symbols are permitted; write out the name of the symbol (i.e. save beta, alpha, etc.). You will be allowed to use symbols for the abstract body.
  • Body:
    • The size of the abstract is limited to 2000 characters including spaces (or approx. 400 words). This includes body of abstract only.
    • The body must contain four separate paragraphs: a) Introduction; b) Methods; c) Results; and d) Conclusions. The abstract should be informative and detailed.
    • Standard abbreviations may be used as follows: on first use, spell out the full term and follow with abbreviation in parentheses. Abbreviations can be used subsequently.
    • Use generic names of drugs.
    • It is NOT acceptable to state that "The results will be discussed." Inclusion of specific data is necessary for reviewers.
    • Indicate the major new findings of the study.
  • References: The references are to be cited in your abstract body. The reference(s) will be placed at the bottom of your abstract automatically after you cite in the “Body” section of the submission process. Cite references sequentially in the body after a punctuation mark.
    Example: Jones A, Smith R, Doe J, et al. AS in prostate cancer management. Can Urol Assoc J 2016;10:201-5
  • Study Groups/Acknowledgements: These will be noted above your abstract in the CUAJ.
  • Figures:
    • To insert a figure (image, table or graph) please upload the files as a JPG in the “Figures” step
    • All tables/graphs must be titled and all images/figures must have a caption.
    • All figures (image, table, or graph) will only be published in the Annual Meeting web app. They will not be published in the printed journal.
    • Reference to accompanying figures must be made within the body of the abstract (i.e., Patient demographics are listed in Table 1). For the printed journal, readers will be directed to view figures on the web app.  
  • Authors:
    • Take care to list ALL authors in the relevant section of the submission site. Spell out completely the names of all authors using full first and last names.
    • Middle name initials are to be placed in the special field for this. It should be a capital letter with a period at the end. (i.e. Stephanie M. Smith)
    • Maintain consistency in author names on multiple abstracts to avoid duplication in the Author Index.
    • Affiliations (department, institution) should be spelled out in full.
  • Presenting Author: If the author(s) of the abstract is an employee(s) of, or has a financial relationship with, the commercial interest, which controls the content of the presentation, he/she cannot be the presenting author. However, investigators responsible for research and development are permitted to present as long as they resolve their Conflict of Interest (COI) and as long as they are not employees of the commercial interest. In all printed publications the presenting author will be underlined.
  • Conflict of Interest and Disclosure Statement: This is required for the submitting author and the presenting author. It is the responsibility of the submitting author to collect this information.
  • Topic List: Authors must select an abstract topic (only one) from the provided list.
    Localized prostate
    Advanced prostate
    Kidney
    Urothelial
    Testes
    Other

C. Conflict of Interest Disclosures for submitting author and presenting author

Prior to submitting an abstract, the submitter must collect the following information from the presenting author (if he/she is not the presenter).

All Presenters and Planning Committee members must complete this form and submit to the Office of Education. Disclosure must be made to the audience whether you do or do not have a relationship with a commercial entity such as a pharmaceutical organization, medical device company, or a communications firm.

Q1. (Yes or No) I have/had an affiliation (financial or otherwise) with a pharmaceutical, medical device or communications organization. Complete the section below as it applies to you during the past two calendar years. Please indicate the commercial organization(s) with which you have/had affiliations, and briefly explain what connection you have/had with the organization. You must disclose this information to your audience.    

If Q1 is yes then list all the activities over the past years for each of the following items AND if the activity is concluded or ongoing. 

  1. I am a Member of an Advisory Board or equivalent with a commercial organization
  2. I am a member of a Speakers bureau
  3. I have received payment from a commercial organization (including gifts or other consideration or ‘in kind’ compensation) 
  4. I have received grant(s) or an honorarium from a commercial organization.
  5. I hold a patent for a product referred to in the CME/CPD program or that is marketed by a commercial organization.
  6. I hold investments in a pharmaceutical organization, medical devices company or communications firm.
  7. I am currently participating in or have participated in a clinical trial within the past two years. 

Q2. (Yes or No) I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. off-label use of medications).

If yes, you must declare all off-label use to the audience during your presentation.


Proudly supported and co-sponsored by
CUOS 2019 sponsors

Contact us

  • CUA CORPORATE OFFICE
    185 Dorval, Suite 401
    Dorval, QC
    H9S 5J9
    Canada
  • (514) 395-0376
    Fax (514) 395-1664

Keep me Posted

First Name
Could not find the language line "frm_error"
Last Name
Could not find the language line "frm_error"
City
Could not find the language line "frm_error"
Country
Could not find the language line "frm_error"
Email
Could not find the language line "frm_error"

Future Dates

  • 74th CUA | June 29th-July 1st, 2019
    QUEBEC CITY, QC
  • 75th CUA | June 27th-30th, 2020
    VICTORIA, BC
  • 76th CUA | June 26th-29th, 2021
    NIAGARA FALLS, ON
  • 77th CUA | June 25th-28th, 2022
    CHARLOTTETOWN, PEI
  • 78th CUA | June 17th-20th, 2023
    MONTREAL, QC